December 3rd 2023
Frontline cadonilimab (AK104) and platinum-based chemotherapy improved progression-free survival in patients with recurrent or metastatic cervical cancer.
November 9th 2023
The median OS achieved with atezolizumab plus bevacizumab and chemotherapy was 32.1 months vs 22.8 months with bevacizumab and chemotherapy alone.
October 24th 2023
The 12-month overall survival rates were 48.7% and 35.3% with tisotumab vedotin and chemotherapy, respectively, among patients with recurrent or metastatic cervical cancer.
October 23rd 2023
Patients who received induction chemotherapy prior to chemoradiation had a 35% reduced risk of progression or death.
October 18th 2023
Cancer screening tests may not extend life expectancy; however, they still are valuable for public health.
Most Americans Are Not Properly Insured for Surgical Lymphedema Treatment
Many Americans with health insurance are not fully covered for frontline procedures to treat lymphedema—a debilitating condition that often affects patients with cancer.
HPV ctDNA Testing Successfully Predicts Recurrence in Cervical Cancer
Liquid biopsies helped determine which patients with cervical cancer were at a high risk of recurrence following chemoradiation.
Vaginal Dilation and Sexual Activity Linked to Lower Sexual Dysfunction Following Cervical Cancer Treatment
Cervical cancer survivors who regularly engage in sex or use vaginal dilators report lower levels of vaginal shortening.
Remote Interventions Increase Cancer Screening Rates Among Women Living in Rural Areas
Patient navigation services increased the rates of breast, cervical, and colorectal cancer screenings 6-fold amongst women living in rural communities.
IMRT Betters Patient-Reported Outcomes in Cervical, Endometrial Cancer
A reduction in patient-reported symptomatic adverse events (AEs) was observed with intensity-modulated radiotherapy (IMRT) compared with standard radiotherapy in patients with cervical or endometrial cancer, whereas no difference was observed with regard to clinician-reported AE.
FDA Approves Entrectinib for Multiple Solid Tumor Indications
The FDA approved entrectinib for pediatric and adult patients with certain subtypes of solid tumors, including non-small cell lung cancer.
HPV Vaccine Continues to Decrease Cervical Precancers in the US
Cervical cancer and precancers have decreased in recent years, thanks to the HPV vaccine.
FDA Places Partial Hold on Axalimogene Filolisbac Trial in Cervical Cancer
The phase III AIM2CERV trial investigating axalimogene filolisbac (AXAL) in patients with cervical cancer has been placed on partial clinical hold by the FDA.
HPV Subtypes Correlated with Higher Risk for High-Grade Cervical Cancer
The presence of HPV-16 and -18 were associated with a higher risk of developing high-grade cervical intraepithelial neoplasia (CIN) in women under the age of 30, study says.
FDA Approves Gardasil 9 to Expand Use in Men and Women Up to Age 45
The Food and Drug Administration (FDA) approved Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) to expand its use in women and men aged 27 to 45 years.
USPSTF Offers Choice in Testing for Women at Average Risk for Cervical Cancer
New guidelines issued by the US Preventive Services Task Force (USPSTF) recommend for women aged 30 to 65 years at average risk for cervical cancer to choose to receive a Pap smear alone every 3 years, screening with the high-risk human papillomavirus test alone, or cotesting every 5 years.
FDA Approves the First Biosimilar to Treat Cancer
The FDA announced today that it has approved the first biosimilar for the treatment of multiple types of cancer.
Better Bowel Function With Pelvic IMRT for Gynecologic Cancers
Pelvic IMRT causes less GI, GU toxicities than standard pelvic radiation therapy for patients with gynecologic cancers.
Study affirms importance of vaccination before exposure to HPV
Canadian researchers led by Salaheddin M. Mahmud, MD, PhD of the University of Manitoba conducted a study to assess the effectiveness of the quadrivalent human papillomavirus (QHPV) vaccine against cervical dysplasia.
Updated Cervical Cancer Screening Guidelines
Women are now advised to have fewer screenings over their lifetime.
Neoadjuvant Pembrolizumab Improves pCR Across ER+ Breast Cancer Subgroups
Tucatinib Continues to Show Benefit in Pretreated HER2+ Breast Cancer With Brain Metastases
Ribociclib Plus Endocrine Therapy Continues to Perform Well Across MONALEESA-2, -3, and -7 Trials
Patient-Reported Outcomes From CAPItello-291 Trial Support Capivasertib/Fulvestrant in HR+, HER2- Advanced Breast Cancer
2 Clarke Drive Cranbury, NJ 08512